ESR1 and breast cancer: Also a potent inhibitory effect has been observed with the combination of BET inhibitors and HDAC inhibitors in triple negative and estrogen receptor positive breast cancer cells, mainly through an induction of the ubiquitin-specific protease (USP17) [43].